Day: July 18, 2025
The Board of Telia Lietuva, AB (hereinafter “Telia Lietuva” or “the Company”) approved unaudited Telia Lietuva, AB Interim Financial Statements, prepared according to International Financial Reporting Standards as adopted by the European Union, for 6 months’ period ended 30 June 2025.
Second quarter of 2025 (compared with the same period a year ago):Revenue grew by 2% and amounted to EUR 121.9 million (2024: EUR 119.5 million)
Adjusted EBITDA up by 8.9% to EUR 48.7 million (2024: EUR 44.7 million)
EBITDA increased by 10.3% and amounted to EUR 48.5 million (2024: EUR 44 million)
Profit for the period went up by 21.3% to EUR 22.1 million (2024: EUR 18.3 million)
Capital investments up by 24.6% and amounted to EUR 14.2 million (2024: EUR 11.4 million)
EUR 64.1 million of dividends were paid for the year 2024 (EUR 0.11 per share) (EUR 52.4...
Clariant rejects LyondellBasell’s allegations against four companies related to the 2020 competition law infringement
Written by Customer Service on . Posted in Public Companies.
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR
Muttenz, 18 July 2025
Clariant, a sustainability-focused specialty chemical company, today announced that on 16 July 2025, the company received a claim for damages against four companies, including Clariant, from LyondellBasell with the court of Amsterdam, The Netherlands. The claim alleges damages totaling to around EUR 1.6 billion in relation to infringement of competition law on the ethylene purchasing market which was sanctioned by the European Commission in July 2020. Clariant firmly rejects the allegation and will adamantly defend its position in the proceedings. Clariant has substantiated economic evidence that the conduct of the parties did not produce any effect on the market.
CORPORATE MEDIA RELATIONS
Jochen DubielPhone +41 61 469 63 63 jochen.dubiel@clariant.com
...
BW Energy: Second quarter 2025 operational update
Written by Customer Service on . Posted in Public Companies.
Second quarter 2025 operational update
BW Energy will publish its financial results for the second quarter and first half of 2025 on 1 August 2025. Today, the company provides preliminary operational figures.
Net production attributable to BW Energy was 2.9 million barrels of oil (mmbbls) in the second quarter 2025, equivalent to 32.3 thousand barrels of oil per day (kbopd), from the Dussafu license in Gabon (73.5% working interest) and the Golfinho field in Brazil (100% working interest).
Q2 2025
Q1 2025
Q2 2024Production (mmbbls)
2.9
3.2
2.1Dussafu
2.4
2.6
1.4Golfinho
0.5 ...
Coop Pank unaudited financial results for Q2 2025
Written by Customer Service on . Posted in Public Companies.
By the end of the Q2 2025, Coop Pank had 218,000 customers, increased by 5,000 customers in the quarter (+2%) and by 22,000 in the year (+11%). The bank had 103,600 active customers, increased by 1,800 (+2%) in the quarter and by 8,300 (+9%) in the year.
In Q2 2025, volume of deposits in Coop Pank decreased by 98 million euros (-5%), reaching total of 1.81 billion euros. The deliberate reduction of deposits is a result of the successful covered bond issuance carried out in the first quarter. Deposits from private clients increasing by 0.4 million euros: demand deposits decreased by 0.4 million euros and term deposits increased by 0.8 million euros. Deposits from domestic business customers decreased by 78 million euros: demand deposits decreased by 10 million euro and term deposits decreased by 68 million euros. Deposits from international...
Press Release: Sanofi completes acquisition of Blueprint Medicines
Written by Customer Service on . Posted in Public Companies.
Sanofi completes acquisition of Blueprint Medicines
Paris, July 18, 2025. Sanofi today announces the completion of its acquisition of Blueprint Medicines Corporation (Blueprint), adding to its portfolio a commercialized medicine, a promising pipeline, and the expertise of a company specializing in systemic mastocytosis (SM), a rare immunological disease, and other KIT-driven diseases.
In addition, the acquisition of Blueprint brings Sanofi an established presence among allergists, dermatologists, and immunologists which is expected to enhance Sanofi’s ability to advance its growing immunology pipeline.
The acquisition includes a rare immunology disease medicine, Ayvakit/Ayvakyt (avapritinib), approved in the US and EU. Ayvakit/Ayvakyt is the only approved medicine for advanced and indolent systemic mastocytosis (ASM & ISM), which...
FACT CHECK: Frequency Holdings YCRM Issues Clarification On Procedural Judgment; No Liability to Company, Litigation Exposure Remains for Luciano Aguayo
Written by Customer Service on . Posted in Public Companies.
CHICAGO, July 17, 2025 (GLOBE NEWSWIRE) — Frequency Holdings Inc. (OTC: YCRM), a Nevada public company, issues this clarification following a press release distributed on July 17, 2025, by Luciano Aguayo, defendant in the original and now-defunct lawsuit brought by ReachOut Technology Corp., a former subsidiary of YCRM.
The judgment referenced in the release has no financial or legal impact on YCRM. The company retains full ownership and operation of reacquired assets, including customer contracts and intellectual property.
YCRM is Not Liable — But the Claims Against Aguayo Remain Alive
The judgment does not affect YCRM. Claims originally brought against Mr. Aguayo, estimated during mediation at over $9 million, were dismissed without prejudice and remain enforceable. These may be reasserted at any time by the current rights holder....
Fairfax Issues Reminder Regarding Unofficial Communications
Written by Customer Service on . Posted in Public Companies.
TORONTO, July 17, 2025 (GLOBE NEWSWIRE) — Fairfax Financial Holdings Limited (TSX: FFH and FFH.U) (“Fairfax”) reminds its shareholders and all persons interested in Fairfax that none of Fairfax, Prem Watsa, nor any officer of Fairfax provides financial or investment advice to any person over social media, chat or messaging applications.
Prem Watsa does not maintain and has never maintained any online social media accounts. Any social media outlet claiming to represent him or to offer advice on his behalf is fraudulent. Impersonation scams are common, and so one should treat any unsolicited electronic communication that references Fairfax or Prem Watsa with extreme caution.
We encourage all persons looking for information about Fairfax and Prem Watsa to consult our press releases, annual reports, interim quarterly reports and annual...
Successful Commercial Launch of Ryoncil®
Written by Customer Service on . Posted in Earnings Releases And Operating Results.
Activity Report for Quarter Ended June 30, 2025 (Appendix 4C)
NEW YORK, July 17, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue from sales of Ryoncil® (remestemcel-L-rknd) through the first quarter post product launch.
Ryoncil® is the first and only FDA approved mesenchymal stromal cell (MSC) product in the Unites States and became commercially available for purchase on March 28, 2025, within one quarter of receiving FDA approval for treatment of steroid-refractory acute graft-versus-host disease (SR-aGvHD) in children.
Mesoblast Chief Executive Dr. Silviu Itescu said, “We are pleased with the commercial launch activities of Ryoncil® in the first quarter post-launch and look forward to updating on the current...